Nicox’s Partner Secures Additional Approval of Vyzulta in Taiwan

Source: Nicox

Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan.

This additional approval brings the total number of countries or territories where Vyzulta is approved for commercialization to six (U.S., Argentina, Canada, Hong Kong, Mexico and Taiwan), marking the continued expansion where regulatory authorities can accept the clinical data from the U.S. new drug application. Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension and is commercialized in the U.S. and Canada.

Nicox receives increasing tiered net royalties of 6% to 12% on global sales of Vyzulta as well as up to $150 million in potential future milestones.



Related Content